- EBRD provides €25 million to Ukraine’s medicines producer Yuria-Pharm
- New production lines will improve access to affordable cancer and other socially significant treatment
Patients in Ukraine will receive access to affordable cancer treatment medication following the launch of new production lines at Yuria-Pharm Group, Ukraine’s leading manufacturer of intensive care medicines, medical devices and antiseptics.
A six-year loan of up to €25 million from the EBRD will help Yuria-Pharm expand its existing production facilities and introduce an innovative solution for the Ukrainian market, which will help customise cancer treatment practices. Healthcare establishments and patients across Ukraine will be able to buy smaller and cheaper doses of specialised medicines.
According to Ukraine’s Healthcare Ministry, over 1 million people in the country have oncological diseases. Medicines required for their treatment are expensive and the state is currently providing only around 30 per cent of the required subsidised or free medication for those in need.
The EBRD is the largest international financial investor in Ukraine. Since the start of its operations in the country in 1993, the Bank has made a cumulative commitment of almost €13.1 billion across some 418 projects in Ukraine.